Measuring blood clotting and inflammation in people with advanced liver cirrhosis
Tests new blood assays for clotting and inflammation in adults with decompensated liver cirrhosis.
Key facts
- Who runs it
- Region Stockholm
- Where
- Stockholm, SwedenSee the site
- Trial code
- Registry title
- Hemostasis in Liver Cirrhosis and Hepatocellular Cancer
- Status
- Recruiting
- People taking part
- 100 people, planned
- Started
- 2 Dec 2022
- Expected to end
- 1 Dec 2028
- Type of study
- Observational, 4 groups
- Treatments tested
- T-TAS
- Record updated
- 19 January 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with decompensated liver cirrhosis. Healthy adults can also join as a comparison group.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Decompensated liver cirrhosis (healthy adults serve as controls).
- Earlier treatment
- No transfusions in the last 7 days. No platelet inhibitors or anticoagulants, except a prophylactic dose of LMWH. No previous liver transplantation.
Main reasons for not taking part
- Cancer outside the liver, or its return, within the last year
- A clotting disorder or thrombophilia diagnosed before joining
- A blood disease such as blood cancer, Polycytemia Vera or hemoglobinopathies
- Previous liver transplantation
- Transfusion in the last 7 days
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Patients with decompensated liver cirrhosis
- 18 years or older
- Healthy individuals 18 years or older will serve as controls
Who cannot take part
- • Extrahepatic malignancy or recurrence of such within the last year; Diagnosis of non-cirrhotic coagulopathy, coagulation disorder or thrombophilia prior to inclusion; Diagnosis of hematological disease such as hematologic malignancies, non-cirrhotic thrombocytopenia or thrombocytosis, Polycytemia Vera, hemoglobinopathies; Previous liver transplantation; Transfusions the last 7 days; Treatment with platelet inhibitors or anticoagulant except for prophylactic dosage of LMWH. If a prophylactic dose of LMWH has been used study sampling with addition of antiFXa must be taken >12 hours after the last injection
Where in Sweden
- Karolinska University HospitalStockholm, SwedenContact: Sanna Norén, MD, PhDstudentTaking people
About the trial
What the trial wants to find out
Evaluating hemostasis in decompensated liver cirrhosis with novel hemostatic assays.
The 4 groups in the trial
- Non-acute decompensated liver círrhosis
Refractory ascites, low grade encephalopathy but manages to stay at home and only come in ofr check-ups.
Treatment: T-TAS
- Acute decompensated liver cirrhosis
Acute event causing further decompensation and the need for in-patient care
Treatment: T-TAS
- Acute on chronic liver failure
ACLF 1-3 accordic to criterias established through the Cannonic study.
Treatment: T-TAS
- Controls
Healthy individuals
Treatment: T-TAS
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Novel Biomarkers for Evaluation of Hemostasis and Inflammation in Liver Cirrhosis
- Plain-language title
- Measuring blood clotting and inflammation in people with advanced liver cirrhosisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 19 January 2024